

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 30, 2021

**DARÉ BIOSCIENCE, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-36395**  
(Commission  
File Number)

**20-4139823**  
(I.R.S. Employer  
Identification No.)

**3655 Nobel Drive, Suite 260**  
**San Diego, CA 92122**

(Address of Principal Executive Offices and Zip Code)

Registrant's telephone number, including area code: **(858) 926-7655**

**Not Applicable**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class  
**Common stock**

Trading Symbol(s)  
**DARE**

Name of each exchange on which registered  
**Nasdaq Capital Market**

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 8.01 Other Events**

Included as Exhibit 99.1 to this report is a presentation about Daré Bioscience, Inc. ("Daré") and its product candidates, dated June 30, 2021, which is incorporated herein by reference. Daré intends to use the presentation and its contents in various meetings with investors, securities analysts and others, commencing on June 30, 2021.

As planned, and as indicated in the presentation included as Exhibit 99.1 to this report, Daré submitted a new drug application ("NDA") to the U.S. Food and Drug Administration ("FDA") for DARE-BV1 for the treatment of bacterial vaginosis during the second quarter of 2021, in June 2021. Daré requested an application fee waiver for the NDA submission, using the small business eligibility criteria available under the Prescription Drug User Fee Act, or PDUFA, and believes it complies with all requirements necessary to receive such fee waiver. Daré also requested priority review status for the NDA upon submission, which, if granted, could allow for a review period of six months from the FDA's receipt of the NDA submission, rather than the 10-month review period for non-priority submissions. Daré expects to receive notice from the FDA before the end of August 2021 regarding its determination whether to accept the NDA submission for filing and proceed with a substantive review. Assuming the FDA accepts the NDA for filing and review, grants priority review, sets a goal date for a decision, or a PDUFA date, within approximately six months from the NDA submission date, and approves the NDA in 2021, Daré would expect a commercial launch of DARE-BV1 in the United States in the first half of 2022. Ongoing strategic discussions and other activities to support a robust market introduction of the product in 2022, if approved, are underway, and Daré intends to finalize and announce the commercialization strategy for DARE-BV1 in the U.S. in 2021. Commercialization arrangements for DARE-BV1 may include granting pharmaceutical companies with other commercial products in women's health out-licenses to exclusively market, sell and distribute the product, if approved, in specific geographies, engaging commercial sales organizations to utilize their internal sales organizations and other commercial functions for market access, marketing, distribution, and other related services, or assembling a hybrid of these potential options to co-promote the product.

**Cautionary Statement Regarding Forward-Looking Statements**

This report contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended, including, without limitation, statements relating to potential FDA review and approval of the DARE-BV1 NDA and commercialization arrangements and timing for DARE-BV1. To the extent that statements contained in this report are not descriptions of historical facts, they are forward-looking statements. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties. Actual results could differ materially from those anticipated as a result of various factors, including, without limitation, the risks and uncertainties inherent in the development of and regulatory review process for Daré's product candidates, including DARE-BV1, and Daré's ability to continue as a going concern. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in the forward-looking statements, as well as risks relating to Daré's business in general, please refer to Daré's annual report on Form 10-K filed with the SEC on March 30, 2021, and its current and future periodic reports filed with the SEC. You are urged to consider these factors carefully in evaluating the forward-looking statements in this report and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. Unless otherwise required by law, Daré expressly disclaims any obligation to update publicly any forward-looking statements, whether as result of new information, future events or otherwise.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

<b>Exhibit No.</b>	<b>Description</b>
99.1	<a href="#">Corporate presentation, dated June 30, 2021</a>


**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: June 30, 2021

**DARÉ BIOSCIENCE, INC.**

By: /s/ Sabrina Martucci Johnson  
Name: Sabrina Martucci Johnson  
Title: President and Chief Executive Officer



# Daré Bioscience

## DARÉ

IN ITALIAN, IT MEANS “TO GIVE.”

IN ENGLISH, IT MEANS “TO BE BOLD.”



## Forward-Looking Statements; Disclaimers

This presentation is for informational purposes only and is not an offer to sell or a solicitation of an offer to buy any securities of Daré Bioscience, Inc. ("Daré" or the "Company"). This presentation includes certain information obtained from trade and statistical services, third-party publications, and other sources. Daré has not independently verified such information and there can be no assurance as to its accuracy.

All statements in this presentation, other than statements of historical fact, are forward-looking statements within the meaning of federal securities laws. In some cases, you can identify forward-looking statements by terms such as "may," "will," "expect," "plan," "anticipate," "strategy," "designed," "could," "intend," "believe," "estimate," "target," or "potential," or the negative of these terms and other similar expressions. Such statements include, but are not limited to, statements relating to the clinical and market potential of Daré's product candidates, clinical trial advancement, timing and data, regulatory approval and commercialization, potential collaborations, benefits of a collaboration, pipeline expansion, and potential funding and financing transactions. As used in this presentation, "first-in-category" and "first-line" are forward-looking statements relating to market potential of a product candidate if it were to receive regulatory approval for the indication(s) for which it is being developed. None of the product candidates presented herein are approved for use outside of clinical trials. The timing of clinical trials, clinical trial data, FDA review and approval, collaborations and other milestones and events relating to development and commercialization of Daré's product candidates, other than those having occurred prior to the date of this presentation, are forward-looking statements. Forward-looking statements reflect management's estimates and expectations based on current information and involve risks, uncertainties and assumptions that may cause Daré's actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements, including, without limitation, as a result of risks and uncertainties inherent in Daré's business and those described in Daré's most recent annual report on Form 10-K and quarterly report on form 10-Q filed with the Securities and Exchange Commission under the heading "Risk Factors." All forward-looking statements are current only as of the date of this presentation. Daré does not undertake any obligation to update any forward-looking statement in this presentation to reflect new information, future developments or otherwise, except as required by law.

All trademarks, service marks or trade names appearing in this presentation are the property of their respective owners. Unless specifically identified as such, Daré's use or display of third-party marks is not intended and does not indicate or imply any relationship with or endorsement or sponsorship of Daré by the third-party owner.

## Women's Health is Our Sole Focus

Daré Bioscience is a clinical-stage biopharmaceutical company committed to addressing the lack of innovation in women's health primarily in the areas of contraception, vaginal health, sexual health, and fertility.

We work to accelerate innovative product options in women's health that...

Expand treatment options,  
Enhance outcomes, and  
Improve ease of use for women.

We partner to...

Drive **innovation** and develop new solutions,

**Accelerate** novel products to **address persistent unmet needs in a time and capital efficient** manner, and

Become a **pipeline resource** for large and emerging commercial companies.

We look for differentiated investigational products with...

**Attractive market opportunities** + unmet medical needs,

Prior human **proof-of-concept** and/or ability to leverage a 505(b)(2) regulatory pathway,

**First-in-category** or first-line potential, and

Opportunity to **personalize for women** with novel, convenient routes of administration.



# Daré Bioscience: A Compelling Opportunity

## Company Highlights

- 1 Diverse pipeline with independent outcomes**  
Several programs, including an NDA stage and four clinical development stage or Phase 1-ready candidates utilizing different APIs and targeting different indications
- 2 Multiple novel delivery platforms**  
Persistent unmet needs require creative new approaches designed for her
- 3 Large market potential**  
First-line or first-in-category product opportunities across the portfolio
- 4 505(b)(2) FDA pathway planned for most candidates**  
Use of well-characterized APIs expected to mitigate development risk, time, and cost
- 5 Commercial value in women's health** evidenced by recent transformational pharma transactions

## Anticipated Program Milestones

- |             |  |
|-------------|--|
| <b>2021</b> | <ul style="list-style-type: none"><li>✓ DARE-BV1 NDA submission to FDA (bacterial vaginosis)</li><li>✓ DARE-HRT1 Phase 1 study topline data (hormone therapy)</li><li>• DARE-VVA1 Phase 1 study commence (vaginal atrophy treatment for women with breast cancer)</li><li>• DARE-BV1 PDUFA date*</li><li>• Sildenafil Cream, 3.6% Phase 2b study topline data (female sexual arousal disorder)</li></ul> |
| <b>2022</b> | <ul style="list-style-type: none"><li>• DARE-BV1 U.S. commercial launch</li><li>• Ovaprene® data from pivotal Phase 3 study (hormone-free monthly contraception)</li><li>• DARE-VVA1 Phase 1 study topline data</li><li>• DARE-FRT1 Phase 1 study commence (preterm birth and IVF luteal phase support)</li></ul>  |

\* Would require a priority review designation from the FDA. DARE-BV1 has Fast Track and Qualified Infectious Disease Product designations from the FDA for treatment of bacterial vaginosis.

# Advancing Products Women Want – Late Stage Programs



PARTNERS	Product Candidate	PRE-CLINICAL	PHASE 1	PHASE 2	PHASE 3 / PIVOTAL	REGULATORY FILING
----------	-------------------	--------------	---------	---------	-------------------	-------------------

## DARE-BV1<sup>A</sup> Bacterial Vaginosis- Phase 3 Topline Data Announced December 2020, NDA submitted 2Q2021

Novel, investigational thermosetting bioadhesive hydrogel single-administration vaginal treatment for bacterial vaginosis. In the DARE-BVFREE Phase 3 study, DARE-BV1 demonstrated the potential for improved clinical cure rates versus current branded FDA-approved marketed products for the treatment of bacterial vaginosis.

Potential first-line option for bacterial vaginosis  
*Bioadhesive gel, clindamycin 2%*



## Ovaprene<sup>®</sup> Hormone-Free, Monthly Contraception- Pivotal Phase 3 Study 6-Month Data 2022

Investigational hormone-free monthly intravaginal contraceptive designed to be an easy-to-use monthly option with effectiveness approaching hormonal methods; commercial partnership agreement with Bayer. There are currently no FDA-approved monthly hormone-free contraceptives.

Potential first-in-category contraception  
*Self-administered intravaginal drug/device*

## Sildenafil Cream, 3.6% <sup>A</sup> Female Sexual Arousal Disorder- Phase 2b Topline Data 2021

Investigational cream formulation of sildenafil, the active ingredient in Viagra<sup>®</sup>, for topical administration to treat FSAD. FSAD is a physiological condition characterized by the inability to attain or maintain sufficient genital arousal during sexual activity, for which there are no FDA-approved treatments. Of the various types of female sexual dysfunction disorders, FSAD is most analogous to erectile dysfunction in men.

Potential first-in-category treatment for female sexual arousal disorder (FSAD)  
*Topical cream, same active ingredient as Viagra<sup>®</sup>*

<sup>A</sup>505(b)(2) regulatory pathway anticipated.


# Advancing Products Women Want – Phase 1 and Preclinical



PARTNERS	Product Candidate	PRE-CLINICAL	PHASE 1	PHASE 2	
		DARE-HRT1 <sup>A</sup> Hormone Therapy - Phase 1 Study Complete			First-in-category combination hormone delivery for treatment of vasomotor and vaginal symptoms of menopause. Intravaginal ring (IVR) designed to release bio-identical estradiol and bio-identical progesterone over 28 days.
NIH		DARE-FRT1 <sup>A</sup> Pregnancy Maintenance - Phase 1 Preparation			First-in-category progesterone delivery for pregnancy maintenance including the prevention of preterm birth and for luteal phase support as part of an IVF regimen. IVR designed to release bio-identical progesterone over 14 days.
		DARE-VVA1 <sup>A</sup> Vulvar and Vaginal Atrophy – Phase 1 Preparation			First-in-category hormone-free vaginal treatment for vulvar and vaginal atrophy (VVA) in a hormone-receptor positive, breast cancer patient population. Proprietary formulation of tamoxifen for vaginal administration.
BILL & MELINDA GATES foundation		DARE-LARC1 <sup>A</sup> Long-Acting, Reversible Personal Contraceptive System			User-controlled levonorgestrel implant drug delivery system is designed to store and precisely deliver hundreds of therapeutic doses over months or years in a single implant that can be wirelessly controlled.
		ORB 204/214 <sup>A</sup> 6 & 12-Month Injectable Contraception			Novel 6 & 12-month injectable formulations of etonogestrel being developed as a longer-acting, reversible method of contraception with a more predictable return to fertility.
		DARE-RH1 Male or Female Contraceptive Target			A potential new rapidly reversible, non-hormonal contraceptive solution with application for women and men.

<sup>A</sup>505(b)(2) regulatory pathway anticipated.

# Near Term Catalysts to Drive Value



\* Would require priority review designation from the FDA. <sup>^</sup>505(b)(2) regulatory pathway anticipated.

# Daré: Advancing Products Women Want

Innovative women's health pipeline with multiple clinical, regulatory and commercial milestones anticipated in 2021-2022.

Every program, if approved, represents a potential first-line or first-in-class product opportunity.

Experienced Board of Directors and Management Team with demonstrated success in clinical and product development, regulatory affairs, corporate strategy and financial operations.

Women's health generating more interest as evidenced by transformational transactions:<sup>1-6</sup>

Pharmaceutical companies will continue to seek new and differentiated products to supplement their branded women's health offerings



Licensed **Ovaprene** from **Daré Bioscience**. Deal includes up to \$310 million in potential commercial milestone payments, plus double-digit, tiered royalties on net sales. **KaNDY** acquisition for upfront consideration of \$425 million.



**Myovant** to receive up to \$4.2 B in collaboration to develop and commercialize **relugolix** in oncology and women's health including up to \$200m in regulatory milestones for the women's health product candidate.



CooperCompanies

Acquired global rights to **PARAGARD®** Intrauterine Device (IUD) from **Teva** in a \$1.1 billion cash transaction.



Acquisition of **Ogeda** for €500 million upfront and the potential for up to another €300 million in milestone payments.



Merck **Organon** spinoff, a new firm focused on women's health (including **NuvaRing**) and other drugs with projected annual revenue of >\$6.5 billion.

<sup>1</sup> <https://www.businesswire.com/DareBioscience>  
<sup>2</sup> <https://www.businesswire.com/KaNDy-Therapeutics-Ltd>  
<sup>3</sup> <https://www.pfizer.com/news/press-releases/press-release-detail/myovant-sciences-and-pfizer-announce-collaboration-develop>  
<sup>4</sup> <https://www.globenewswire.com/The-Cooper-Companies-Announces-Definitive-Agreement-to-Acquire-PARAGARD-IUD-From-Teva>  
<sup>5</sup> <https://www.biopharmadive.com/news/astellas-ogeda-womens-health-deal>  
<sup>6</sup> <https://www.organon.com/news/organon-launches-as-new-global-womens-health-company/>

# Experienced Management & Board of Directors

## Management Team

 **Sabrina Martucci Johnson**  
MSc, MIM  
President & CEO

 **John Fair**  
Chief Strategy Officer

 **Lisa Walters-Hoffert**  
Chief Financial Officer

 **David Friend, PhD**  
Chief Scientific Officer

 **Mary Jarosz, RPh, RAC, FTOPRA**  
Global Head of Regulatory Affairs

 **Mark Walters**  
Vice President of Operations

 **Christine Mauck, MD, MPH**  
Medical Director

## Board of Directors

 **William Rastetter, PhD**  
Chairman

 **Greg Matz, CPA**

 **Cheryl Blanchard, PhD**

 **Sophia N. Ononye-Onyia, PhD, MPH, MBA**

 **Jessica Grossman, MD**


 **Robin Steele, JD, LLM**

 **Susan Kelley, MD**

 **Sabrina Martucci Johnson**  
MSc, MIM  
President & CEO



We are delivering **innovation** by **daring to be different**®



**DARE-BV1  
Clindamycin  
2% gel for  
Bacterial  
Vaginosis**

**Best-in-class curative potential for the  
most common<sup>1</sup> vaginal infection in  
women of reproductive age, designed for  
convenient, one-time administration  
NDA submitted 2Q 2021**

1.<https://www.cdc.gov/std/bv/stats.htm>

10

---

## Bacterial Vaginosis - What is the clinical issue?

### Recurring infection, difficult to treat effectively

- ▶ Most common vaginal infection in women ages 15-44, affecting ~21 million women in the US<sup>1</sup>
- ▶ Current Rx suboptimal: clinical cure rates of 37-68%<sup>2</sup>

### Bacterial Vaginosis increases health risk<sup>3</sup>

- ▶ Preterm birth – bacterial vaginosis is linked to premature deliveries, low birth weight babies
- ▶ Sexually transmitted infections – bacterial vaginosis increases susceptibility to HIV, herpes simplex virus, chlamydia, gonorrhea
- ▶ Post-surgical infection – bacterial vaginosis may increase risk of infection after gynecologic procedures
- ▶ Pelvic inflammatory disease – bacterial vaginosis may cause PID, an infection that affects women's reproductive organs and can increase the risk of infertility

<sup>1</sup><https://www.cdc.gov/std/bv/stats.htm>  
<sup>2</sup>Bacterial vaginosis product data: <http://www.clindeesse.com/pdf/PI.pdf>; [http://www.accessdata.fda.gov/drugsatfda\\_docs/label/2014/205223s000lbl.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205223s000lbl.pdf);  
[http://www.accessdata.fda.gov/drugsatfda\\_docs/label/2014/205223s000lbl.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205223s000lbl.pdf)  
<sup>3</sup><https://www.mayoclinic.org/diseases-conditions/bacterial-vaginosis/symptoms-causes/syc-20352279>

# DARE-BV1- Phase 3 Study Design & Demographics<sup>1</sup>

DARE-BV1 is a thermosetting vaginal gel formulated with clindamycin phosphate 2%, a well-known and well-characterized antibiotic designed for prolonged, localized release.

► DARE-BVFREE randomized 307 women at 32 centers across the US in a 2:1 ratio to receive a single vaginal dose of DARE-BV1 (N=204) or a single vaginal dose of placebo gel (N=103).

► The intent to treat (ITT) population<sup>2</sup> comprised primarily patients aged 15 to 59 years, with a mean age of 34.8 (6=8.8) and median age of 35. Over 53% of the ITT population qualified as obese (BMI  $\geq 30.0$ ), with a mean BMI of 31.50 (6=8.5).

► In the ITT population, 56.0% of women identified as Black or African American, 41% identified as white and 25.5% identified as of Hispanic or Latino origin (compared to 74.5% as not of Hispanic or Latino origin).

► In addition, more than 75% of women in the ITT population reported one or more episodes of bacterial vaginosis in the 12 months before they were randomized into the study (77.4% in the DARE-BV1 group and 73.8% in the placebo group).

► The mITT study population<sup>3</sup> also required a **Nugent score of 7 or greater** at time of randomization per the new 2019 FDA bacterial vaginosis guidance.

#### Definitions:

**Primary Endpoint:** Clinical Cure (Day 21-30 visit)<sup>4</sup>: Resolution of the abnormal vaginal discharge associated with BV; Negative 10% KOH "whiff test"; Clue cells < 20% of the total epithelial cells in the saline wet mount.

**Secondary endpoints:** Proportion of subjects with Clinical Cure, Bacteriological Cure and Therapeutic Cure at Day 7-14 Visit<sup>5</sup>

**Bacteriological Cure:** a Nugent score < 4.

**Therapeutic Cure:** both a Clinical Cure and Bacteriological Cure.

The DARE-BVFREE study's two treatment arms were well balanced in terms of age, race, ethnicity, bacterial vaginosis history, and body mass index (BMI).



N=307 subjects enrolled (age 15 and above)  
Duration ~30 days per subject  
Diagnosis - Bacterial vaginosis

1. Data on file.

2. ITT population N=307

3. Modified ITT (mITT) population N=180. In accordance with FDA guidance, the mITT population excludes subjects from the ITT population who subsequently demonstrated a positive test result for other concomitant vaginal or cervical infections at baseline.

4. Visit occurred 21 to 30 days after study drug administration.

5. Visit occurred 7 to 14 days after study drug administration.

## DARE-BV1: Potential for Improved Clinical Cure Rates vs. Current Branded Rx

Product	Frequency, Dose, and Route of Administration	Study Descriptions	Clinical Cure Rates	
 <b>DARE-BV1</b> (Investigational) (clindamycin phosphate vaginal gel, 2%)	1 time, 5g applicator, applied vaginally	<div style="border: 1px solid black; padding: 5px; display: inline-block;">                         Randomized Placebo-Controlled Phase 3 Trial<sup>1</sup>                          Topline data                     </div> DARE-BVFREE (Day 21-30) <i>Modified-Intent-to-Treat Population at 21-30 Days</i> DARE-BVFREE (Day 7-14) <i>Modified-Intent-to-Treat Population at 7-14 Days</i> DARE-BVFREE (Day 21-30) <i>Per Protocol Population at 21-30 Days</i> DARE-BVFREE (Day 7-14) <i>Per Protocol Population at 7-14 Days</i>	DARE-BV1 (N=121) Placebo (N=59) DARE-BV1 (N=121) Placebo (N=59) DARE-BV1 (N=101) Placebo (N=47) DARE-BV1 (N=101) Placebo (N=47)	70.5% 35.6% 76.2% 23.7% 77.5% 42.6% 81.4% 29.8%
 Solosec® (secnidazole 2g oral granules)	1 time, 2g dose, taken orally	Two Randomized, Placebo-Controlled Phase 3 Studies <sup>2</sup> Study 1 (Day 21-30) <i>Modified-Intent-to-Treat Population at 21-30 Days</i> Study 2 (Day 21-30) <i>Modified-Intent-to-Treat Population at 21-30 Days</i> Study 2 (Day 7-14) <i>Modified-Intent-to-Treat Population at 7-14 Days</i>	SOLOSEC (N=62) Placebo (N=62) SOLOSEC (N=107) Placebo (N=57) SOLOSEC (N=107) Placebo (N=57)	67.7% 17.7% 53.3% 19.3% 57.9% 24.6%
 Clindesse® (clindamycin phosphate vaginal cream, 2%)	1 time, 5g applicator, applied vaginally	Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study <sup>3</sup> Study 1 (Day 21-30) <i>Modified-Intent-to-Treat Population at 21-30 Days</i> Randomized, Investigator-Blind, Active-Controlled Comparative Study Study 2 (Day 21-30) <i>Modified-Intent-to-Treat Population at 21-30 Days</i> Study 2 (Day 21-30) <i>Per Protocol Population at 21-30 Days</i>	Clindesse (N=78) Placebo (N=66) Clindesse Single Dose (N=223) Clindamycin Vaginal Cream, 7 doses (N=211) Clindesse Single Dose (N=124) Clindamycin Vaginal Cream, 7 doses (N=125)	41.0% 19.7% 53.4% 54.0% 64.3% 63.2%
 Nuvessa™ (metronidazole vaginal gel 1.3%)	1 time, 5g applicator, applied vaginally	Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study <sup>4</sup> Study 1 (Day 21-30) Study 1 (Day 7)	NUVESSA (N=292) Vehicle Gel (N=285) NUVESSA (N=292) Vehicle Gel (N=285)	37.0% 26.7% 41.1% 20.0%

1. Data on file  
 2. SOLOSEC. PRESCRIBING INFORMATION <https://dailymed.nlm.nih.gov/dailymed/lookupDrug.cfm?setid=551e43d5-f700-4d6e-8009-026f8a89276a>  
 3. Clindesse. PRESCRIBING INFORMATION <https://www.clindesse.com/pdf/PI.pdf>  
 4. NuVessa. PRESCRIBING INFORMATION [https://www.nuvessa.com/nuvessa\\_files/nuvessa%20PI%202018.08.pdf](https://www.nuvessa.com/nuvessa_files/nuvessa%20PI%202018.08.pdf)

## DARE-BV1: Looking Forward

DARE-BV1 delivered **better clinical cure rate values than currently marketed FDA-approved products** for treatment of bacterial vaginosis.<sup>1</sup>  
DARE-BVFREE Study:

► 71% at Day 21-30 (primary endpoint) and 76% at Day 7-14 in the mITT population, and **rates of 78% at Day 21-30 and 81% at Day 7-14 in the per protocol population.**<sup>2</sup>

► Demonstrated that DARE-BV1 is significantly effective in what we believe was a representative patient population, including a large proportion of patients who reported one or more episodes of bacterial vaginosis in the 12 months before they were randomized into the study (75% of the ITT population).

► **Consistent clinical cure rates even in the subset of women who reported having 3 or more prior bacterial vaginosis episodes in the last year.**<sup>3</sup>

► Based on pre-NDA meeting with FDA early 2021, **NDA submitted 2Q2021.**

► **NDA may qualify for priority review and, if granted, receive a 2021 PDUFA date, permitting potential 2022 commercial launch in the U.S.**

DARE-BV1  
Qualified  
Infectious  
Disease Product  
(QIDP) and Fast  
Track  
Designations

Priority  
Review  
Requested

1. Based on topline data from the Phase 3 DARE-BVFREE study and the prescribing information for currently marketed products.

2. For more detail regarding topline study results see our December 7, 2020 announcement available at: <https://ir.darebioscience.com/news-releases/news-release-details/dare-bioscience-announces-positive-topline-results-dare-bvfree>; the per protocol population (N=148) includes subjects from the mITT population who have no major protocol violations that impact the primary or secondary endpoints or who received any other bacterial vaginosis therapy for any reason.

3. Prior episodes were self reported




**Sildenafil  
Cream, 3.6%**

**Potential First-In-Category treatment for Female Sexual Arousal Disorder (FSAD), which has no FDA-approved therapies**

**Novel cream formulation of sildenafil to treat FSAD, utilizing active ingredient in Viagra®**

**Female Sexual Arousal Disorder (FSAD)** is characterized primarily by inability to attain or maintain sufficient genital arousal during sexual activity and, of female sexual function disorders, is most analogous to **erectile dysfunction (ED)** in men.\*



**The condition should be distinguished from** a general loss of interest in sexual activity and from other sexual dysfunctions, such as orgasmic disorder (anorgasmia) and **hypoactive sexual desire disorder (HSDD)**, which is characterized as lack or absence of sexual fantasies and desire for sexual activity for some period of time.<sup>1,2</sup>

\*Diagnostic and Statistical Manual 4th Edition Text Revision (DSM IV TR), defines female sexual arousal disorder as a persistent or recurrent inability to attain or to maintain until completion of the sexual activity, an adequate lubrication–swelling response of sexual excitement. The diagnostic criteria also state that the inability causes marked distress or interpersonal difficulty, is not better accounted for by another Axis I disorder (except another sexual dysfunction) and is not due exclusively to the direct physiological effects of a substance (e.g., a drug of abuse, a medication) or a general medical condition.

<sup>1</sup><https://drgeo.com/womens-sexual-health-overview/>;

<sup>2</sup><https://health.usnews.com/conditions/sexual-disorder-dysfunction>


## FSAD – What Is the Incidence?

Meta-analysis of 95 studies from 2000-2014 indicated prevalence of **Female Sexual Dysfunction in premenopausal women worldwide is 41%**, and **difficulty with arousal alone is 23%**.<sup>1</sup>

Market research estimates:

► **33%** of US women aged 21 to 60 (~ **20 million women**), experience symptoms of low or no sexual arousal.<sup>2,3</sup>

► **10 million women** are considered distressed and actively seeking treatment.<sup>2</sup>



1. McCool et al. Sex Med Rev 2016;4:197-212.  
2. Ad Hoc Market Research: FSAD Prevalence Report (Oct 2015) conducted for SST LLC.  
3. Based on US Census projections for 2016.

### Topically administered investigational Sildenafil Cream<sup>1</sup> is...

- ▶ A PDE5 inhibitor utilized in ED medications for men – ED product Viagra<sup>®</sup> peaked at \$2.05 billion in sales in 2012.<sup>2</sup>
- ▶ Designed to increase local blood flow to provide improvement in genital arousal response.
- ▶ **Applied topically**, avoiding hepatic first-pass metabolism response, resulting in lower systemic exposure potentially resulting in reduced side effects vs. oral sildenafil, including Viagra<sup>®</sup>
- ▶ Given **similarities between ED and FSAD**, sildenafil – the active ingredient in Viagra<sup>®</sup> – may improve genital arousal response and overall sexual experience for women as it does in men.

### There are no FDA-approved treatments for FSAD

<sup>1</sup>Sildenafil Cream, 3.6%, (formerly SST-6007)

<sup>2</sup><https://qz.com/quartz/1238783/its-the-20th-anniversary-of-viagra-heres-how-its-changed-the-world/#:~:text=Annual%20sales%20of%20Viagra%20peaked,Viagra%20is%20set%20to%20expire>

## Sildenafil Cream, 3.6% - Phase 2b

Ongoing Phase 2b clinical study aims to evaluate Sildenafil Cream vs. placebo over 12 weeks of dosing following both a non-drug and placebo run-in period.

- ▶ Compares Sildenafil Cream vs. placebo used in patients' home setting.
- ▶ Primary endpoint: patient reported outcome (PRO) instruments to measure improvement in localized genital sensations of arousal and reduction in FSAD related distress.
- ▶ Several exploratory efficacy endpoints will be measured and could become additional measurements of efficacy in a future Phase 3 program.




# Oral Sildenafil provided a compelling proof of concept for FSAD

## Statistically significant increases in Vaginal Pulse Amplitude (VPA)<sup>1</sup> Pfizer VPA Clinical Lab Study – Oral Viagra



<sup>†</sup> Twelve healthy premenopausal women were studied.

## Statistically significant improvement in genital stimulation (FIEI)<sup>2</sup> Pfizer Clinical Field Study – Oral Viagra



<sup>†</sup> Question #2 – “After taking study medication, the sensation/feeling in my genital (vaginal, labia, clitoris) area during intercourse or stimulation (foreplay) seemed to be: (a) more than before, (b) less than before, or (c) unchanged”.

Question #4 – “After taking the study medication, intercourse and/or foreplay was: (a) pleasant and satisfying; better than before taking the study medication, (b) unpleasant; worse than before taking study medication, (c) unchanged; no difference, or (d) pleasant; but still not like it used to be or I would like it to be.”

202 postmenopausal women with FSAD who had protocol specified estradiol and free testosterone concentrations, and/or were receiving estrogen and/or androgen replacement therapy were studied.

### Key Takeaways of Viagra<sup>®</sup> studies:

- Increased blood flow and clinical efficacy observed with oral sildenafil (Viagra<sup>®</sup>) in women.
- The side effect profile of the oral formulation was not optimal for women - leading to the exploration of alternative delivery options including a topical route of administration.

<sup>1</sup>The Enhancement of Vaginal Vasocongestion by Sildenafil in Healthy Premenopausal Women. Journal of Women's Health & Gender-Based Medicine. Vol. 11, No. 4. 2002  
<sup>2</sup>Safety and Efficacy of Sildenafil Citrate for the Treatment of FSAD: A Double-Blind, Placebo Controlled Study. The Journal of Urology. Vol 170, 2333-2338, December 2003.

# Sildenafil Cream, 3.6% - Phase 1 and Phase 2a Study Results

## Phase 1 Study of SST-6007 (Sildenafil Cream, 3.6%)<sup>1</sup>

Normal healthy postmenopausal women were dosed with escalating doses of Sildenafil Cream, 3.6%, using a cross-over study design.

- Sildenafil Cream had significantly lower systemic exposure compared to a 50 mg oral sildenafil dose
- AUC – 3-6%
- C<sub>max</sub> – 1-2%
- Sildenafil Cream was safe and well tolerated at clinically relevant doses (1-2g)
- Favorable product characteristics as self-reported by subjects
- Easy to use
- Readily absorbed

## Phase 2a Study of SST-6007 (Sildenafil Cream, 3.6%)<sup>1</sup>


Demonstrated increased blood flow in the genital tissue compared to placebo (mean change in VPA analysis) in 31 women (pre and postmenopausal) ~30 minutes post dosing.

1. Data on file. Sildenafil Cream, 3.6% was previously known as SST-6007.

## Phase 1 Study

Treatment	N=59	Sildenafil Single Dose	C <sub>max</sub> (ng/ml)	T <sub>max</sub> (hr)	AUC <sub>0-∞</sub> (h*ng/ml)
Topical Sildenafil 1 g of cream	20	35 mg	3.4	2.37	25.6
Topical Sildenafil 2 g of cream	20	71 mg	3.8	2.27	30.8
Topical Sildenafil 4 g of cream	19	142 mg	5.3	2.22	42.5

## Phase 1 Study




# Sildenafil Cream, 3.6% - Thermography Study Results

Demonstrated time to effect (See Figure 1)

- Positive cognitive arousal responses were noted.
- Significantly greater increases in genital temperature after application of Sildenafil Cream compared to placebo cream.
- Significantly greater self-reported arousal responses reported during Sildenafil Cream visits compared to placebo cream visits.

Figure 1. Clitoral temperature change during the sexually explicit film



Statistically significant greater linear slope during minutes 11-15 of the sexually explicit stimuli as compared to the placebo cream for the vestibule.

## Thermography Study Design & Methodology (N=6)<sup>1</sup>

Phase 1, single-dose, double-blind, placebo-controlled, 2-way crossover study evaluating the feasibility of using thermography to assess the pharmacodynamics of Sildenafil Cream, 3.6% in normal healthy women. The study required 3 visits and a follow up contact: Visit 1 (screening), Visits 2-3 (double-blind dosing) and a phone call (safety follow-up).

1. Data on file.

\* Thermography utilizes sensitive cameras capable of detecting and recording temperature variations over time. Genital temperature changes are a surrogate for genital blood flow.



Ovaprene®

Investigational potential first-in-  
category, hormone-free, monthly birth  
control

Partnered With 

# Ovaprene® - Commercial License Agreement with Bayer<sup>1</sup>

January 2020 - Bayer, which markets the \$1 billion Mirena contraceptive franchise, and Daré announced the execution of a license agreement under which Bayer may commercialize Ovaprene investigational contraceptive in the US once approved by FDA.



Mirena® is the #1 prescribed IUD in the U.S.\*

- Bayer received the right to obtain exclusive US rights to commercialize the product, following completion of the pivotal clinical trial if Bayer, in its sole discretion, pays Daré \$20 million.

- Daré may receive up to \$310 million in commercial milestone payments, plus double-digit, tiered royalties on net sales.

- Bayer supports the development and regulatory process by providing up to two full-time equivalents (internal experts) in an advisory capacity, which gives Daré access to their global manufacturing, regulatory, medical and commercial expertise.


*We believe the licensing agreement with Bayer is validation of our broader corporate strategy and confirmation of Ovaprene's market potential, if approved, as the first monthly non-hormonal contraceptive product in the US market.*

\* <https://www.mirena-us.com/>; supported by 2014-2016 SHS data.

1. <https://ir.darebioscience.com/news-releases/news-release-details/bayer-and-dare-bioscience-announce-exclusive-licensing-agreement>

# Contraception: Large Market Opportunity

## Women in the Reproductive Health & Contraception Market Segment (over 60 million women)



Source: US Census Bureau, 2017 National Dataset (2016 is base population estimate for projection) <https://www.census.gov/programs-surveys/popproj.html>

## Successful Contraceptive Brands Peak Sales:



**Mirena® Hormone IUD**  
(levonorgestrel-releasing intrauterine system) 52mg  
Physician inserted, long-acting, low/locally delivered hormone IUS  
**2019 worldwide sales: €1.2 billion (Bayer)<sup>1</sup>**



**Lo Loestrin®**  
(norethindrone acetate and ethinyl estradiol, ethinyl estradiol tablets)  
Lowest amount of daily estrogen (10 micrograms) available in pill form  
**2019 US sales: \$588 million (Allergan)<sup>2</sup>**




**NuvaRing®**  
(etonogestrel/ethinyl estradiol vaginal ring)  
Monthly vaginal ring  
**2019 worldwide sales: \$879 million (Merck)<sup>3</sup>**

<sup>1</sup><https://www.bayer.com/en/bayer-ag-annual-report-2019.pdf>. Includes sales for Mirena®, Kyleena® and Jaydess® / Skyla®  
<sup>2</sup><https://www.prnewswire.com/news-releases/allergan-reports-fourth-quarter-and-full-year-2019-financial-results-301001646.html>  
<sup>3</sup>[https://s21.q4cdn.com/488056881/files/doc\\_financials/2019/q4/2019-FORM-10-K-Final.pdf](https://s21.q4cdn.com/488056881/files/doc_financials/2019/q4/2019-FORM-10-K-Final.pdf)


# Ovaprene® - Potential Market Opportunity

There are approximately 65 million women in the US Aged 15-44<sup>1</sup>



<sup>1</sup>Source: CDC National Survey for Family Growth, 2013-2015 dataset, cdc.gov.  
<sup>2</sup>Market research study conducted in 2019 for Daré Bioscience  
<sup>3</sup>Contraceptive use data applied to 2019 population data from US Census

# Contraception: What's Missing from Current Hormone-free Options?



<sup>1</sup>U.S. Food and Drug Administration Birth Control Guide dated 6/14/2021: <https://www.fda.gov/consumers/free-publications-women/birth-control-chart>  
<sup>2</sup>U.S. Food and Drug Administration Drug Data Prescribing information for a vaginal gel approved in 2020, Phexxi™ provides that in a multicenter, open-label, single-arm clinical trial in the U.S. (AMP002; NCT03243305), the 7-cycle cumulative pregnancy rate was 13.7% (95% CI: 10.0%, 17.5%), excluding cycles with back-up contraception, cycles <21 or > 35 days in length and cycles in which no intercourse was reported. The estimated Pearl Index, calculated based on data from the 7-cycle study, was 27.5 (95% CI: 22.4%, 33.5%).  
[https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2020/208352s000lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208352s000lbl.pdf)  
<sup>\*</sup> Pregnancy rates tell you the number of pregnancies expected per 100 women during the first year of typical use. Typical use shows how effective the different methods are during actual use (including sometimes using a method in a way that is not correct or not consistent). For more information on the chance of getting pregnant while using a method or on the risks of a specific product, please check the product label or Trussell, J. (2011). "Contraceptive failure in the United States." Contraception 83(5):397-404.

# Ovaprene® Investigational Hormone-Free, Monthly Contraceptive

Physical Barrier<sup>6</sup>  
Three-dimensional,  
knitted polymer  
barrier



Spermiostatic Environment<sup>6</sup>  
Contraceptive-loaded silicone ring  
releasing non-hormonal active  
Ferrous gluconate

Desired Features of  
Birth Control Products:<sup>1-4</sup>

Design Features of Ovaprene:<sup>5-7</sup>

+ Efficacy

86% - 91% Expected Typical Use Effectiveness  
Approaching Hormone Contraception

+ Hormone Free

No Hormones in the API  
Unique dual action MOA (spermiostatic & barrier)

+ Convenience

Monthly Ring Form  
Women choose monthly intravaginal products for  
the convenience of a non-daily option

+ Favorable Side  
Effect Profile

Safety Profile Similar to a Diaphragm  
No significant changes in vaginal flora and no  
serious adverse effects observed in studies to date

+ Easily Manage  
Fertility

No Systemic/Long-term Activity  
Inserted and removed without a provider allowing  
for immediate return to fertility

<sup>1</sup><https://www.urban.org/urban-wire/women-want-effective-birth-control>

<sup>2</sup>Lesard, J., Perspectives on Sexual and Reproductive Health, Volume 44, Number 3, 9-2012

<sup>3</sup>Hooper, DJ, Clin Drug Investig, 2016; 30(11):749-63

<sup>4</sup>Ersek, J, Matern Child Health J (2011) 15:497-506

<sup>5</sup>In PCT studies of similar size, products (diaphragms) that demonstrated no motile sperm in the cervical mucus during PCT assessments later demonstrated "typical use" contraceptive effectiveness of 86-91% in pivotal contraceptive studies evaluating pregnancy rates over six-month periods. Mauck C, Vincent K. Biology of Reproduction, Volume 103, Issue 2, August 2020, Pages 437-444

<sup>6</sup>Journal of Reproductive Medicine 2009; 54: 685-690

<sup>7</sup>Trussell J. Contraceptive Efficacy. In Hatcher RA, Trussell J, Nelson AL, Cates W, Kowal D, Polcar M. Contraceptive Technology: Twentieth Revised Edition. New York, NY: Ardent Media, 2011.

# Ovaprene<sup>®</sup> - U.S. Regulatory Strategy<sup>1</sup>

Premarket approval (PMA) strategy –  
The Center for Devices and Radiological Health (CDRH) as lead review division

## Step 1 (Completed)

• Postcoital Test (PCT) Clinical Study - Completed 4Q 2019

## Step 2 (Ongoing)

1 - File investigational device exemption (IDE) to support 1Q2022 pivotal study start.

- 2 - Conduct pivotal study
- Six-month efficacy and safety data expected by year-end 2022
  - ~250 completers up to 12 months of use
  - Primary endpoints: safety and efficacy (pregnancy probability)
  - Secondary endpoints: acceptability, product fit/ease of use and assessments of vaginal health

### The PCT Clinical Study Met its Primary Endpoint

Ovaprene prevented the requisite number of sperm from reaching the cervix across all women and all cycles evaluated.

• Specifically, in 100% of women and cycles, an average of less than five (< 5) progressively motile sperm (PMS) per high-powered field (HPF) were present in the midcycle cervical mucus collected two to three hours after intercourse with Ovaprene in place.

• Women enrolled in the study who completed at least one Ovaprene PCT (N=26) had a mean of 27.21 PMS/HPF in their baseline cycle (without any contraceptive device), a mean of 0.22 PMS/HPF in their diaphragm cycle (in the presence of an FDA-cleared diaphragm with spermicide), and a mean of 0.48 PMS/HPF in their Ovaprene PCT cycles (in the presence of the Ovaprene device), with a median of zero PMS.

	Mean Progressively Motile Sperm	Median Progressively Motile Sperm	Standard Deviation	Interquartile Range
Baseline PCT's	27.21	23.20	17.88	24.80
Ovaprene PCT's	0.48	0.00	1.18	0.10

• In PCT studies of similar size, products (diaphragms) that demonstrated no motile sperm in the cervical mucus during PCT assessments later demonstrated "typical use" contraceptive effectiveness of 86–91% in pivotal contraceptive studies evaluating pregnancy rates over six-month periods.<sup>2</sup>

<sup>1</sup> Anticipated regulatory pathway and timelines.  
<sup>2</sup> Mauck C, Vincent K. Biology of Reproduction, Volume 103, Issue 2, August 2020, Pages 437–444



## Milestones and Catalysts

---

## Near Term Catalysts to Drive Value

### 2019 and 2020

- ✓ June 2019 – Positive findings of Sildenafil Cream, 3.6% thermography clinical study
- ✓ Nov. 2019 – Positive topline data for Ovaprene® postcoital test clinical study
- ✓ Jan. 2020 – Exclusive licensing agreement with Bayer for Ovaprene
- ✓ May/Sept 2020 – Strategic partnerships with Health Decisions / Avomeen
- ✓ Sept. 2020 – Bill & Melinda Gates Foundation grant funding for DARE-LARC1 reaches \$20.5 million
- ✓ Dec. 2020 – Positive topline data for DARE-BV1 Phase 3 study

### Anticipated Milestones

#### 2021

- ✓ DARE-BV1 NDA submission to FDA
- ✓ DARE-HRT1 Phase 1 study topline data
- DARE-BV1 PDUFA date\*
- DARE-VVA1 Phase 1 study commence
- Sildenafil Cream, 3.6% topline data for Phase 2b study

#### 2022

- DARE-BV1 U.S. commercial launch
- Ovaprene® data from pivotal Phase 3 study
- DARE-VVA1 Phase 1 study topline data
- DARE-FRT1 Phase 1 study commence

\* Would require priority review designation from the FDA.

# Phase 1 and Preclinical Programs

*New investigational prescription drug  
delivery options for women*

# Advancing Products Women Want – Phase 1 and Preclinical



PARTNERS	Product Candidate	PRE-CLINICAL	PHASE 1	PHASE 2	
		<b>DARE-HRT1<sup>A</sup> Hormone Therapy - Phase 1 Study Complete</b>			First-in-category combination hormone delivery for treatment of vasomotor and vaginal symptoms of menopause. Intravaginal ring (IVR) designed to release bio-identical estradiol and bio-identical progesterone over 28 days.
		<b>DARE-FRT1<sup>A</sup> Pregnancy Maintenance - Phase 1 Preparation</b>			First-in-category progesterone delivery for pregnancy maintenance including the prevention of preterm birth and for luteal phase support as part of an IVP regimen. IVR designed to release bio-identical progesterone over 14 days.
		<b>DARE-VVA1<sup>A</sup> Vulvar and Vaginal Atrophy – Phase 1 Preparation</b>			First-in-category hormone-free vaginal treatment for vulvar and vaginal atrophy (VVA) in a hormone-receptor positive, breast cancer patient population. Proprietary formulation of tamoxifen for vaginal administration.
		<b>DARE-LARC1<sup>A</sup> Long-Acting, Reversible Personal Contraceptive System</b>			User-controlled levonorgestrel implant drug delivery system is designed to store and precisely deliver hundreds of therapeutic doses over months or years in a single implant that can be wirelessly controlled.
		<b>ORB 204/214<sup>A</sup> 6 &amp; 12-Month Injectable Contraception</b>			Novel 6 & 12-month injectable formulations of etonogestrel being developed as a longer-acting, reversible method of contraception with a more predictable return to fertility.
		<b>DARE-RH1 Male or Female Contraceptive Target</b>			A potential new rapidly reversible, non-hormonal contraceptive solution with application for women and men.

<sup>A</sup>505(b)(2) regulatory pathway anticipated.

# Intravaginal Ring Technology (IVR) Highlights

## The Vaginal Route of Drug Administration<sup>1</sup>

- ▶ Vaginal drug delivery offers many potential advantages due to large surface area, dense network of blood vessels and high elasticity due to presence of smooth muscle fibers.
- ▶ Recognized advantages include comparable ease of administration and ability to bypass hepatic first-pass metabolism.

## Our Intravaginal Ring (IVR) Technology – Design Features:

- ▶ **Sustained** drug delivery,
- ▶ **Variable** dosing and duration,
- ▶ Solid ethylene vinyl acetate (EVA) polymer matrix that can contain and release one or several active drugs,
- ▶ No need for membrane or reservoir to contain active drug(s) or control the release.



<sup>1</sup>Sonia, T.A. & Sharma, C.P., "Routes of administration of insulin – Vaginal route," Oral Delivery of Insulin, 2014, <https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/vaginal-drug-delivery>

Combination bio-identical estradiol + bio-identical progesterone 28-day IVR for hormone therapy following menopause

## 45M women in U.S. approaching or in menopause<sup>1</sup>

### Hormone Therapy (HT)

HT remains the most effective treatment for vasomotor symptoms (VMS) and genitourinary syndrome of menopause (GSM); and has been shown to prevent bone loss and fracture.<sup>2</sup>

•The 2017 Hormone Therapy Position Statement of **The North American Menopause Society** (NAMS), supports HT in peri- and post-menopausal women.<sup>2</sup>

NAMS observes: **non-oral routes may offer advantages** over oral routes of administration.<sup>2</sup>

### Completed Phase 1 STUDY

A Phase 1, Open-Label, 3-arm Parallel Group Study to Evaluate the Pharmacokinetics and Safety of DARE-HRT1 (80 µg and 160 µg Estradiol/ 4 mg and 8 mg Progesterone Intravaginal Rings) in Healthy Post-Menopausal Women.

The topline data from the study support DARE-HRT1's potential to be the first FDA-approved product to offer **vaginal delivery** of combination bio-identical estradiol and bio-identical progesterone hormone therapy in a convenient **monthly format** to treat both VMS as well as vaginal symptoms of menopause.

505(b)(2) candidate<sup>3</sup>

<sup>1</sup>U.S. Census Bureau, Population Division. Table 2. 2015 to 2060 (NP2012-T2). Released Dec. 2012.

<sup>2</sup>The 2017 hormone therapy position statement of The North American Menopause Society; Menopause: The Journal of The North American Menopause Society Vol. 24, No. 7, pp. 728-753. <https://www.menopause.org/docs/default-source/2017/nams-2017-hormone-therapy-position-statement.pdf>

<sup>3</sup>Anticipated regulatory pathway. Daré has not had any communications with the FDA regarding the specific marketing approval requirements for DARE-HRT1

## Bio-identical progesterone 14-day IVR for prevention of preterm birth and luteal phase support as part of an IVF treatment plan

### Prevention of Preterm Birth (PTB)

After steadily declining from 2007 to 2014, the US premature birth rate rose for the fourth straight year in 2018 with ~10% of babies born preterm (<37 weeks).<sup>3</sup>



### NIH Grant Funding for DARE-FRT1 PTB Program

Potential for up to \$2.3 million in NIH grant funding to support DARE-FRT1 development  
 • Notice of award for initial \$300,000 in grant funding announced Aug 2020.  
 Eunice Kennedy Shriver National Institute of Child Health & Human Development of the National Institutes of Health Award Number R44 HD101169.

### Assisted Reproductive Technologies (ART)/IVF

As women wait longer to have children, infertility risk increases  
 • ~12-15% of couples cannot conceive after 1-year of unprotected sex.  
 • ~20% of US women have their first child after age 35; ~1/3 of couples in which the woman is older than 35 years have fertility problems.



#### 505(b)(2) candidate

1. Anticipated regulatory pathway. Daré has not had any communications with the FDA regarding the specific marketing approval requirements for DARE-FRT1  
 2. 2019 March of Dimes Report Card, <https://www.marchofdimes.org/mission/reportcard.aspx>  
 3. CDC's National Center for Health Statistics, National Vital Statistics Reports, Births: Final Data for 2018, Nov 27, 2019, [https://www.cdc.gov/nchs/data/nvsr/nvsr68/nvsr68\\_13-508.pdf](https://www.cdc.gov/nchs/data/nvsr/nvsr68/nvsr68_13-508.pdf)  
 4. <https://www.nichd.nih.gov/health/topics/infertility/conditioninfo/common> accessed January 8, 2021  
 5. <https://www.cdc.gov/reproductivehealth/infertility/index.htm> accessed January 8, 2021  
 6. Harris Williams & Co. Fertility market overview. May 2015.

Proprietary tamoxifen formulation for vaginal administration for vulvar and vaginal atrophy (VVA), a chronic condition characterized by pain during intercourse, vaginal dryness and irritation

Potential to be the first therapeutic specifically approved for treatment of VVA in patients with hormone-receptor positive (HR+) breast cancer.

- Approximately 3.8 million US women have a history of breast cancer; HR+ is the most common type.<sup>2</sup>
- Localized estrogen therapy for VVA may be contraindicated for women diagnosed with, or at risk of recurrence of, ER-positive and PR-positive breast cancer.
- VVA prevalence in postmenopausal breast cancer survivors is estimated at **42 to 70%**.<sup>3</sup>



Daré is developing this novel local application of tamoxifen to mitigate the symptoms of VVA for HR+ breast cancer patients, including women currently on anti-cancer therapy.

505(b)(2) candidate

<sup>1</sup>Anticipated regulatory pathway. Daré has not had any communications with the FDA regarding the specific marketing approval requirements for DARE-VVA1.

<sup>2</sup>American Cancer Society, Breast Cancer Facts & Figures 2019-2020, <https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/breast-cancer-facts-and-figures-2019-2020.pdf>

<sup>3</sup>Clinical Breast Cancer, Dec 2017: <https://www.sciencedirect.com/science/article/pii/S1526820917300952>

## DARE-VVA1 - Proof of Concept

This exploratory study<sup>1</sup> in four postmenopausal women diagnosed with VVA demonstrated that a self-administered vaginal suppository containing tamoxifen (20mg) dosed daily for one week and twice weekly for three months was effective in reducing vaginal pH and vaginal dryness.

Vaginal Tamoxifen	Enrollment (Baseline)	On Treatment (Month 3)	Paired Difference (Baseline vs. Month 3)
<b>Median Vaginal pH</b> Normal vaginal pH is usually less than 4.5. <sup>2</sup>	7.1 range 6.5 to 7.5	5.0 range 5.0 to 5.2	-2.0 median range -2.5 to -1.5 Lower pH value is a measure of symptom relief
<b>Vaginal Dryness</b> Rated using a visual analogue scale (VAS) that ranged from: 0 = Not bothered by dryness 10 = Extremely bothered by dryness	8.0 range of 7.5 to 9.0	3.0 range 2.0 to 3.0	-5.5 median range -6.0 to -4.5 Decreased vaginal dryness is a measure of symptom relief

In addition, systemic absorption of tamoxifen was not significant:

- After 8 weeks of study treatment with vaginal tamoxifen, median plasma concentration of tamoxifen was 5.8 ng/ml, with a range of 1.0 to 10.0 ng/ml
- In comparison, after 3 months of administration of 20mg, once-daily oral tamoxifen citrate (Nolvadex),<sup>3</sup> the average steady state plasma concentration of tamoxifen is 122 ng/ml with a range of 71 to 183 ng/ml

<sup>1</sup>Clin. Exp. Obstet. Gynecol. - ISSN: 0390-6663 XLVI, n. 2, 2019


<sup>2</sup><https://www.medicalnewstoday.com/articles/322537.php>

<sup>3</sup>US Food and Drug Administration: "Drug Approval Package: Nolvadex (Tamoxifen Citrate) NDA# 21-109.2002". Available at: [https://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2002/21109\\_Nolvadex.cfm](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21109_Nolvadex.cfm)

# DARE - LARC1

User-Controlled Long-Acting Reversible Personal Contraceptive System – levonorgestrel implant drug delivery system is designed to store and precisely deliver hundreds of therapeutic doses over months or years in a single implant that can be wirelessly controlled.

The Bill & Melinda Gates Foundation has strong interest in family planning  
~215 million women in developing countries lack access to contraception



505(b)(2) candidate

1. Anticipated regulatory pathway. Daré has not had any communications with the FDA regarding the specific marketing approval requirements for DARE - LARC1



# Financial Summary

---

## Daré Financial Summary

### 1Q-2021 Financial Highlights:

- Cash provided from financing activities: \$11.4 million (net of fees)
- Cash and equivalents (at 3/31/2021): \$7.7 million

### April 1 through May 10, 2021 Update:

- Cash provided from financing activities: \$2.6 million (net of fees)
- Common shares o/s: ~ 49.4 million shares
- Warrants o/s: ~1.9 million

### Funding sources:

- Since inception, we have raised cash through sale of equity securities, M&A transactions, warrant and option exercises, non-dilutive grants, and license fees
- We endeavor to be creative and opportunistic in seeking capital required to advance our candidates, and to be efficient in use of such capital

Financing activities included sales of stock and warrant exercises.

 **DARING TO BE DIFFERENT® AND  
ADVANCING PRODUCTS WOMEN WANT**



**DARE**



**TO BE**



**BOLD**

